ATC Group: N02AF02 Nalbuphine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02AF02 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02A Opioids
4 N02AF Morphinan derivatives
5 N02AF02 Nalbuphine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 80 mg

Active ingredients in N02AF02

Active Ingredient Description
Nalbuphine

Nalbuphine is an opioid with kappa-agonistic and mu-antagonistic properties. Beside the essential agonistic (analgesic) effect nalbuphine has antagonistic effects of about a fourth of nalorfine and ten times of pentazocine.

Related product monographs

Title Information Source Document Type  
NALPAIN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NUBAIN Solution for injection Health Products and Food Branch (CA) MPI, CA: SPM

Medicines in this ATC group

Austria (AT)

Brazil (BR)

Canada (CA)

Estonia (EE)

France (FR)

Hong Kong (HK)

Ireland (IE)

Poland (PL)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.